Compare Amgen, Inc. (AMGN) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? Amgen, Inc. trades at $356.71 (market cap $196.12B), while Banco Bilbao Vizcaya Argentaria SA trades at $25.48 (market cap $141.88B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (4.2%). Which is the better fit depends on your goals.
| AMGN | BBVA | |
|---|---|---|
Market Cap | $196.12B | $141.88B |
Sector | Health | Financials |
52-Week High | $388.16 | $26.14 |
52-Week Low | $271.18 | $14.73 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BBVA trades at $25.69, up 1.3% with a bullish technical outlook supported by moving averages. The bank shows strong fundamentals with 26.51% net income margin and 18.67% ROE, though recent legal challenges from Spain's High Court regarding a spying case present headwinds. Earnings have mostly beaten expectations, with Q1 2026 EPS of $0.60 exceeding the $0.57 forecast.
The stock offers value with a P/E of 12.39 and receives strong analyst support (53.85% buy ratings), but investors should weigh regulatory risks and volatile cash flows against the positive earnings trajectory and technical momentum for medium-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
